Heavy Menstrual Bleeding Clinical Practice Guideline Inpatient Management

FINAL: 2/3/21 Page 1 of




Inclusion Criteria: Menstruating females with concern for heavy bleeding

Exclusion Criteria:

- Previously identified bleeding disorder (Rheumatology, Cancer, Anti-Coagulation, Congenital Heart Disease)
- Patients with altered mental status, severe hypotension, requiring intubation, or who are otherwise clinically unstable

Algorithm



Definitions

• ppd = pads per day

Considerations

- If known history of blood thinners, consult Hematology
- Start iron when patient tolerating PO
- If unstable/hypotension, consider
 PICU transfer

General Care

- Monitor vitals per routine
- Obtain orthostatic blood pressure and HR on admission and Qshift
- Start IV if indicated
- Case management consult for discharge medication needs

¹Symptoms of Anemia

- Tachycardia
- Orthostatic hypotension
- Headache/Dizziness
- Fatigue

²Bleeding Improved

- <3 ppd
- Orthostasis resolved
- Fatigue resolved
- No headache/dizziness

³ Discharge Criteria

- Tolerating PO
- In room air
- No longer bleeding or only spotting
- No longer orthostatic

⁴ Discharge Instructions

- Follow-up with Gynecologist at CHOA Pediatric Gynecology office (404.785.1491), or Hughes Spalding Adolescent Medicine Clinic (404.785.9850) in 2-4 weeks
- Follow-up with the Hematology Clinic (404.785.1319) in 4-8 weeks to complete bleeding disorder work-up
- Continue hormone taper until daily regimen achieved. If bleeding recurs, return to previous dose and call PCP.
 Do not take placebo pills until seen for follow-up (see Table 1).
- Physician should work with case manager when writing discharge hormone therapy orders to ensure access to the necessary quantity.
- Continue iron supplementation and encourage iron rich foods
- Keep menstrual calendar
- Provide teaching sheet: "When Your Child Has Iron-Deficiency Anemia"

Heavy Menstrual Bleeding Clinical Practice Guideline Inpatient Management

2/3/21 Page 2 of 2



Box 1: Screening Questions (Adapted from Claire Philipp Screening tool; AMJOG 2011)

- 1. On average does your period last 7 or more days?
- 2. Do you experience "flooding" or overflow bleeding thru your tampon or pad?
- 3. Do you need to change your tampon or pad more than every 1-2 hours at times during your period?
- 4. Have you ever been treated (PO iron, IV iron, blood transfusion) for iron deficiency anemia in the past?
- 5. Do you have a family history of a bleeding disorder?
- 6. Have you had excessive bleeding with a dental extraction or dental surgery?
- 7. Have you had excessive bleeding with a miscarriage or following delivery of a child?

Considered to be positive if answered yes to any of the above questions

Box 2: Labs (if not already obtained)

Obtain: Ferritin & Iron panel. CBC Q12H while bleeding (can be more frequent if heavy bleeding), then QD | Urine Pregnancy and Type & Screen

- If Obesity (BMI ≥95%), Acanthosis Nigricans, Hirsutism, or missed period for more than 3 months in a row:
 - Prior to starting hormone therapy, draw FSH, LH, Estradiol, Prolactin, Testosterone. Results not needed prior to starting therapy.
- If sexually active: Consider Urine GC/Chlamydia, Serum RPR and HIV
- If strong personal history of bleeding or family history of bleeding disorder: Consider VWD profile, PT, PTT, and fibrinogen

Table 1: N	/ledications										
10.010 27 10	Hormone Therapy for Admitted Patients					Discharge Hormone Therapy					
Medication	Indications	Dosage Dosage	Max Dose	Contraindications/Comments	Medication	Indications	Dosage	Max Dose	Contraindications/Comments	Presciption Note	
Preferred Oral	Use if ALL of the following are	TAPER: 10 mg BID until 3 days after	10 mg/dose	Contraindication: Previous intolerance	Norethindrone Acetate		TAPER: 10 mg BID until 3	10 mg/dose	Contraindication: Previous	Prescribe 90 tabs	
Norethindrone Acetate	true: -Tolerating PO -Hemodynamically Stable -Hgb >5 - Soaking ≤6 ppd	bleeding stops. Then, start maintenance dose. MAINTENANCE: 10 mg once a day until follow-up appointment.**	20 11/9/ 4000	Not a preferred method of birth control	Preferred	Recommended maintenance/discharge hormone therapy if no contraindications present	days after bleeding stops. Then, start maintenance dose. MAINTENANCE: 10 mg once a day until follow-up	10 11197 4030	intolerance Not a preferred method of birth control	for 30 days with 1 refill	
Preferred IV Conjugated Estrogens (Premarin)	Justif actively bleeding and at least <u>ONE</u> of the following is true: -Unable to tolerate PO -Hypotensive -Hgb ≤5 - Soaking >6 ppd	- 25 mg IV Q4H until bleeding stops or 6 doses have been given - Then, switch to oral hormone therapy.	25 mg/dose	Common Contraindications: Personal history of thrombosis or stroke, thrombosis in first degree relative or family history of hypercoagulability, migraine with aura, SBP >160 or DBP >100, of weeks post-partum, congenital heart disease, active cancer, renal failure, or uncontrolled rheumatologic disease.* Call Hemotology or Gynecology if contraindications present		present	appointment.**				
Altemate Oral Lo-Ovral	Alternate if: -Norrethindrone acetate is contraindicated	1 tab PO Q8H until discharge	1 tab/dose	Common Contraindications: Personal history of thrombosis or stroke, thrombosis in first degree relative or family history of hypercoagulability, migraine with aura, SBP >160 or DBP >100, <6 weeks post-partum, congenital heart disease, active cancer, renal failure, or uncontrolled rheumatologic disease.* Call Hematology or Gynecology if contraindications present	Lo-Ovral Alternote	Alternate if: - Norethindrone acetate is contraindicated	TAPER: - 1 tab PO Q8H x 3 days from initiation - Then, 1 tab PO Q12H x 2 days Then, start maintenance dose MAINTENANCE: 1 tab PO QD until follow-up.*	1 tab/dose	Alternate for Medicaid Patients: Seasonique (uses same dosing schedule as Lo-Ovral) Common Contraindications: Personal history of thrombosis or stroke, thrombosis in first degree relative or family history of hypercoagulability, migraine with aura, SBP >160 or OBP >100, <6 weeks post-partum, congenital heart disease, active cancer, renal failure, or uncontrolled rheumatologic disease.* Call Hematology or Gynecology if if contraindications present	Lo-owal: Prescribe as a 1- month supply with 3 refills Seasonique: Prescribe one 84- pill pack with 1 refill	
Alternate Oral Medroxyprogesterone	Alternate if: -Norethindrone acetate and Lo- Ovral are contraindicated	TAPER: 20 mg BID until 3 days after bleeding stops. Then, start maintenance dose. ** MAINTENANCE: 20 mg once a day until follow-up appointment.	20 mg/dose	Contraindication: Previous intolerance Not a method of birth control.	Medroxyprogesterone Alternate	Alternate if: - Lo-ovral and Norethindrone acetate are contraindicated	TAPER: 20 mg BID until 3 days after bleeding stops. Then, start maintenance dose. ** MAINTENANCE: 20 mg once a day until follow-up appointment.		Contraindication: Previous intolerance Not a preferred method of birth control	Prescribe as 90 tabs per 30 days with 1 refill	
Other Inpatient Medications					Other Discharge Medications						
Medication	Indications	Dosage	Max Dose	Contraindications/Comments	Medication	Indications	Dosage	Max Dose	Contraindications	Presciption Note	
Ferrous Sulfate (Iron)	Recommended for all admitted patients	325 mg (65 mg elemental iron) PO BID		N/A	Ferrous Sulfate (Iron)	Recommended for all patients	325 mg (65 mg elemental iron) PO BID		N/A	Prescribe 60 tabs for 30 days with : refill	
Ondansetron (Zofran) As needed	For side effects related to hormone therapy	0.15 mg/kg PO or IV Q8H as needed	8 mg/dose	N/A	Ondansetron (Zofran) As needed	If oral hormone therapy given	0.15 mg/kg PO Q8H as needed	8 mg/dose	N/A	Prescribe per patient's needs	
Famotidine (Pepcid) As needed	For side effects related to hormone therapy	20 mg PO or IV BID	20 mg/dose	N/A	Famotidine (Pepcid) As needed	If oral hormone therapy given	20 mg PO BID	20 mg/dose	N/A	Prescribe per patient's needs	
Docusate (Colace) As needed	If iron given	50-100 mg QD	100 mg/dose	N/A	Docusate (Colace) As needed	If iron given	50-100 mg PO QD	100 mg/dose	N/A	Prescribe per patient's needs	
	Α	Antifibrinolytics (Admitted patients only)				•					
Medication Aminocaproic acid (Amicar)	Indications For patients soaking >3 ppd after 24 hours on hormone therapy	Dosage - 100 mg/kg IV or PO x1 loading dose, - Then 50 mg/kg IV or PO Q6H	Max Dose 5 g/dose	Contraindications/Comments Contraindication: Hematuria Consult Hematology if using Amicor or							
Tranexamic acid	For patients soaking >3 ppd after 24 hours on hormone therapy	10 mg/kg IV Q8H OR 1300 mg PO TID Criteria for Contraceptive Use	IV: 600 mg/dose PO: 1300 mg/dose	Tranexamic acid							

^{*}Refer to CDC Summary of Medical Eligibility Criteria for Contraceptive Use for complete list of contraindications for estrogens

lf bleeding recurs, return to previous dose and call PCP. Skip placebo pills until seen for follow-up: